Bicara Therapeutics (BCAX) stock plunges as the company reports data from a Phase 1/1b trial for its lead drug ficerafusp alfa in head & neck cancer. Read more here.
Booz Allen reported FQ4 adjusted earnings that matched estimates but revenues that came up short, and issued soft FY 2026 guidance alongside layoffs due to federal cost-cutting efforts.